There are 2789 resources available
1284P - Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC
Presenter: Bo Gao
Session: ePoster Display
1255P - Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
Presenter: Niels Reinmuth
Session: ePoster Display
8P - The characterization of tumors associated with the antitumor activity of lenvatinib plus anti-PD-1 antibody combination therapy in a mouse syngeneic model panel
Presenter: Yoichi Ozawa
Session: ePoster Display
9P - Click Activated Protodrugs Against Cancer (CAPAC) platform enhances the safety, pharmacokinetics, and antitumor efficacy of cancer therapies in vivo
Presenter: Sangeetha Srinivasan
Session: ePoster Display
10P - DS-6000a, a novel CDH6-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
Presenter: Hirokazu Suzuki
Session: ePoster Display
11P - Profiling adaptive responses of renal cell cancer to cabozantinib in order to develop rational drug combinations
Presenter: Diego Tosi
Session: ePoster Display
12P - The design and development of novel pentaranes: Paving the way to EMT inhibition in triple-negative breast cancer cells
Presenter: Alexander Scherbakov
Session: ePoster Display
14P - Preclinical evaluation of intermittent dosing regimens on antitumor and PD activity of SY-5609, a potent and selective oral CDK7 inhibitor, in ovarian cancer xenografts
Presenter: Liv Johannessen
Session: ePoster Display
15P - Modified sialoglycan by neuraminidase promotes tumor immunity against epithelial ovarian cancer
Presenter: Huang mei
Session: ePoster Display